Page 137 - 2020年17期

with HIV receiving highly active antiretroviral therapy YUT R，et al. Pharmacokinetic interactions between qui-
and concomitant medications[J]. Int J Risk Saf Med，2017， nine and lopinavir/ritonavir in healthy Thai adults[J]. Am J
29（1/2）：25-55. Trop Med Hyg，2015，93（6）：1383-1390.
[19] LI TY，LIU W，CHEN K，et al. The influence of combina- [29] 王雪，董迪，甄健存.硼替佐米所致62例不良反应文献分
tion use of CYP450 inducers on the pharmacokinetics of 析[J].中国医院药学杂志，2017，37（24）：2467-2470.
voriconazole：a systematic review[J]. J Clin Pharm Ther， [30] 王延涛，夏玉朝，余孝东，等.洛匹那韦-利托那韦与硼替
2017，42（2）：135-146. 佐米合用导致肝损伤的回顾性研究[J].中南药学，2019，
[20] BOULANGER C，ROLLA V，AL-SHAER MH，et al. 17（11）：1958-1962.
Evaluation of super-boosted lopinavir/ritonavir in combi- [31] FREISE KJ，HU B，SALEM AH. Impact of ritonavir dose
nation with rifampicin in HIV-1-infected patients with tu- and schedule on CYP3A inhibition and venetoclax clinical
berculosis[J]. Int J Antimicrob Agents，2020. DOI： pharmacokinetics[J]. Eur J Clin Pharmacol，2018，74（4）：
10.1016/j.ijantimicag.2019.10.021. 413-421.
[21] RABIE H，DENTI P，LEE J，et al. Lopinavir-ritonavir su- [32] YOGANATHAN K，ROBERTS B，HEATLEY MK.Life-
per-boosting in young HIV-infected children on rifampi- threatening digoxin toxicity due to drug-drug interactions
cin-based tuberculosis therapy compared with lopina- in an HIV-positive man[J]. Int J Std Aids，2017，28（3）：
vir-ritonavir without rifampicin：a pharmacokinetic model- 297-301.
ling and clinical study[J]. Lancet HIV，2018. DOI：10. [33] BEDNASZ C，LUQUE AE，ZINGMAN BS，et al. Lipid-
1016/S2352-3018（18）30293-5. lowering therapy in HIV-infected patients：relationship
[22] RAWIZZA HE，DARIN KM，OLADOKUN R，et al. Safe- with antiretroviral agents and impact of substance-related
ty and efficacy of rifabutin among HIV/TB-coinfected disorders[J]. Curr Vasc Pharmacol，2016，14（3）：280-
children on lopinavir/ritonavir-based ART[J]. J Antimi- 287.
crob Chemother，2019，74（9）：2707-2715. [34] DE KANTER CT，KEUTER M，VAN DER LEE MJ，et
[23] LIN HC，LU PL，CHANG CH. Uveitis associated with al. Rhabdomyolysis in an HIV-infected patient with im-
concurrent administration of rifabutin and lopinavir/ritona- paired renal function concomitantly treated with rosuvas-
vir（Kaletra）[J]. Eye：Lond，2007，21（12）：1540-1541. tatin and lopinavir/ritonavir[J]. Antivir Ther，2011，16（3）：
[24] VAN DER LAAN LE，GARCIA-PRATS AJ，SCHAAF 435-437.
HS，et al. Pharmacokinetics and drug-drug interactions of [35] GORDON LA，MALATI CY，HADIGAN C，et al.Lack of
lopinavir-ritonavir administered with first- and second- an effect of ritonavir alone and lopinavir-ritonavir on the
line antituberculosis drugs in HIV-infected children treat- pharmacokinetics of fenofibric acid in healthy volunteers
ed for multidrug-resistant tuberculosis[J]. Antimicrob [J]. Pharmacotherapy，2016，36（1）：49-56.
Agents Chemother，2018.DOI：10.1128/AAC.00420-17. [36] DAI L，LIU A，ZHANG H，et al. Impact of lopinavir/rito-
[25] PANDIE M，WIESNER L，MCILLERON H，et al. Drug- navir and efavirenz-based antiretroviral therapy on the li-
drug interactions between bedaquiline and the antiretrovi- pid profile of Chinese HIV/AIDS treatment-naive patients
rals lopinavir/ritonavir and nevirapine in HIV-infected pa- in Beijing：a retrospective study[J]. Curr Hiv Res，2019，17
tients with drug-resistant TB[J]. J Antimicrob Chemother， （5）：324-334.
2016，71（4）：1037-1040. [37] PELUFO-PELLICER A，LOPEZ-MONTENEGRO SM.
[26] RATTANAPUNYA S，CRESSEY TR，RUEANGWEERA- Toxicity for warfarine switching from lopinavir/ritonavir
YUT R，et al. Pharmacokinetic interactions between arte- to dolutegravir[J]. Farm Hosp，2017，41（2）：315-316.
sunate-mefloquine and ritonavir-boosted lopinavir in [38] XU R，GE W，JIANG Q.Application of physiologically
healthy Thai adults[J]. Malar J，2015.DOI：10.1186/ based pharmacokinetic modeling to the prediction of
s12936-015-0916-8. drug-drug and drug-disease interactions for rivaroxaban
[27] KREDO T，MAUFF K，WORKMAN L，et al.The interac- [J]. Eur J Clin Pharmacol，2018，74（6）：755-765.
tion between artemether-lumefantrine and lopinavir/ritona- [39] ITKONEN MK，TORNIO A，LAPATTO-REINILUOTO
vir-based antiretroviral therapy in HIV-1 infected patients O，et al. Clopidogrel increases dasabuvir exposure with or
[J]. BMC Infect Dis，2016. DOI：10.1186/s12879-016- without ritonavir，and ritonavir inhibits the bioactivation
1345-1. of clopidogrel[J]. Clin Pharmacol Ther，2019，105（1）：
[28] RATTANAPUNYA S，CRESSEY TR，RUEANGWEERA- 219-228.

中国药房 2020年第31卷第17期 China Pharmacy 2020 Vol. 31 No. 17 ·2175 ·